Shares of Indivior PLC (NASDAQ: INDV), a global pharmaceutical company specializing in substance use disorders, plummeted over 23% in the pre-market session on Thursday.
The sharp decline came after the company issued its guidance for fiscal year 2025, which was weaker than expected. According to the guidance, Indivior anticipates net revenue of $955 million to $1.025 billion for FY 2025, representing a 17% decrease at the midpoint compared to FY 2024.
Specifically, the company expects its SUBLOCADE net revenue to be in the range of $725 million to $765 million, which is relatively flat compared to FY 2024. However, the guidance suggests an accelerated decline in net revenue from SUBOXONE Film due to increased generic competition and the potential impact from a fifth buprenorphine/naloxone sublingual film generic entering the U.S. market.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。